Literature DB >> 29073364

Genetic, Immunologic, and Environmental Basis of Sarcoidosis.

David R Moller1, Ben A Rybicki2, Nabeel Y Hamzeh3, Courtney G Montgomery4, Edward S Chen1, Wonder Drake5, Andrew P Fontenot6.   

Abstract

Sarcoidosis is a multisystem disease with tremendous heterogeneity in disease manifestations, severity, and clinical course that varies among different ethnic and racial groups. To better understand this disease and to improve the outcomes of patients, a National Heart, Lung, and Blood Institute workshop was convened to assess the current state of knowledge, gaps, and research needs across the clinical, genetic, environmental, and immunologic arenas. We also explored to what extent the interplay of the genetic, environmental, and immunologic factors could explain the different phenotypes and outcomes of patients with sarcoidosis, including the chronic phenotypes that have the greatest healthcare burden. The potential use of current genetic, epigenetic, and immunologic tools along with study approaches that integrate environmental exposures and precise clinical phenotyping were also explored. Finally, we made expert panel-based consensus recommendations for research approaches and priorities to improve our understanding of the effect of these factors on the health outcomes in sarcoidosis.

Entities:  

Keywords:  environment; genetics; granuloma; immunology; phenotype

Mesh:

Year:  2017        PMID: 29073364      PMCID: PMC5822412          DOI: 10.1513/AnnalsATS.201707-565OT

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  88 in total

1.  Association between exposure to crystalline silica and risk of sarcoidosis.

Authors:  V Rafnsson; O Ingimarsson; I Hjalmarsson; H Gunnarsdottir
Journal:  Occup Environ Med       Date:  1998-10       Impact factor: 4.402

2.  Functional variant ANXA11 R230C: true marker of protection and candidate disease modifier in sarcoidosis.

Authors:  F Mrazek; A Stahelova; E Kriegova; R Fillerova; M Zurkova; V Kolek; M Petrek
Journal:  Genes Immun       Date:  2011-05-12       Impact factor: 2.676

3.  Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis.

Authors:  Ikuo Ishige; Yoshinobu Eishi; Tamiko Takemura; Intetsu Kobayashi; Koh Nakata; Isao Tanaka; Sakae Nagaoka; Kazuro Iwai; Kunitomo Watanabe; Touichiro Takizawa; Morio Koike
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2005-03       Impact factor: 0.670

4.  M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.

Authors:  Stefan Prokop; Frank L Heppner; Hans H Goebel; Werner Stenzel
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Sarcoidosis is associated with a truncating splice site mutation in BTNL2.

Authors:  Ruta Valentonyte; Jochen Hampe; Klaus Huse; Philip Rosenstiel; Mario Albrecht; Annette Stenzel; Marion Nagy; Karoline I Gaede; Andre Franke; Robert Haesler; Andreas Koch; Thomas Lengauer; Dirk Seegert; Norbert Reiling; Stefan Ehlers; Eberhard Schwinger; Matthias Platzer; Michael Krawczak; Joachim Müller-Quernheim; Manfred Schürmann; Stefan Schreiber
Journal:  Nat Genet       Date:  2005-02-27       Impact factor: 38.330

6.  Common patterns and disease-related signatures in tuberculosis and sarcoidosis.

Authors:  Jeroen Maertzdorf; January Weiner; Hans-Joachim Mollenkopf; Torsten Bauer; Antje Prasse; Joachim Müller-Quernheim; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

7.  Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis.

Authors:  P J Foley; D S McGrath; E Puscinska; M Petrek; V Kolek; J Drabek; P A Lympany; P Pantelidis; K I Welsh; J Zielinski; R M du Bois
Journal:  Am J Respir Cell Mol Biol       Date:  2001-09       Impact factor: 6.914

8.  Human leukocyte antigen-DR alleles influence the clinical course of pulmonary sarcoidosis in Asian Indians.

Authors:  Surendra K Sharma; Arumugam Balamurugan; Ravindra M Pandey; Pradip Kumar Saha; Narinder K Mehra
Journal:  Am J Respir Cell Mol Biol       Date:  2003-02-14       Impact factor: 6.914

9.  Annexin A11 gene polymorphism (R230C variant) and sarcoidosis in a Portuguese population.

Authors:  A Morais; B Lima; M Peixoto; N Melo; H Alves; J A Marques; L Delgado
Journal:  Tissue Antigens       Date:  2013-09

10.  Molecular analysis of sarcoidosis tissues for mycobacterium species DNA.

Authors:  Wonder Puryear Drake; Zhiheng Pei; David T Pride; Robert D Collins; Timothy L Cover; Martin J Blaser
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

View more
  28 in total

1.  Sarcoidosis-associated Hospitalizations in the United States, 2002 to 2012.

Authors:  Aprielle B Wills; Jennifer Adjemian; Joseph R Fontana; Claudia A Steiner; Shelby Daniel-Wayman; Kenneth N Olivier; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2018-12

2.  A case of Graves' disease developing with exacerbation of sarcoidosis.

Authors:  Shinya Makino; Chisako Yagi; Mariko Naka; Sachie Hirose; Masayoshi Fujiwara; Chiho Ohbayashi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 3.  Executive Summary of the NHLBI Workshop Report: Leveraging Current Scientific Advancements to Understand Sarcoidosis Variability and Improve Outcomes.

Authors:  Lisa A Maier; Elliott D Crouser; William J Martin; Jerry Eu
Journal:  Ann Am Thorac Soc       Date:  2017-12

4.  The Immunogenetics of Granulomatous Diseases.

Authors:  Gizem Filazi Kök; Ümit Türsen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.

Authors:  Julie H Wu; Sotonye Imadojemu; Avrom S Caplan
Journal:  Am J Clin Dermatol       Date:  2022-05-18       Impact factor: 6.233

6.  Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.

Authors:  Audrey Melin; Émilie Routier; Séverine Roy; Pauline Pradere; Jerome Le Pavec; Thibaut Pierre; Noémie Chanson; Jean-Yves Scoazec; Olivier Lambotte; Caroline Robert
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

Review 7.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

Review 8.  Application of "Omics" and Systems Biology to Sarcoidosis Research.

Authors:  Elliott D Crouser; Tasha E Fingerlin; Ivana V Yang; Lisa A Maier; Patrick Nana-Sinkam; Ronald G Collman; Naftali Kaminski
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 9.  Arrhythmias in Cardiac Sarcoidosis Bench to Bedside: A Case-Based Review.

Authors:  Lynda E Rosenfeld; Mina K Chung; Clifford V Harding; Paolo Spagnolo; Johan Grunewald; Jason Appelbaum; William H Sauer; Daniel A Culver; Jose A Joglar; Ben A Lin; Christine L Jellis; Timm-Michael Dickfeld; Deborah H Kwon; Edward J Miller; Paul C Cremer; Frank Bogun; Jordana Kron; Ashley Bock; Davendra Mehta; Paul Leis; Konstantinos C Siontis; Elizabeth S Kaufman; Thomas Crawford; Peter Zimetbaum; Edwin T Zishiri; Jagmeet P Singh; Kenneth A Ellenbogen; Jonathan Chrispin; Syed Quadri; Logan L Vincent; Kristen K Patton; Steven Kalbfleish; Thomas D Callahan; Francis Murgatroyd; Marc A Judson; David Birnie; David R Okada; Christopher Maulion; Pavan Bhat; Lavanya Bellumkonda; Ron Blankstein; Richard K Cheng; Maryjane A Farr; Jerry D Estep
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-02-16

Review 10.  Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.

Authors:  Nisha A Gilotra; Jan M Griffin; Noelle Pavlovic; Brian A Houston; Jessica Chasler; Colleen Goetz; Jonathan Chrispin; Michelle Sharp; Edward K Kasper; Edward S Chen; Ron Blankstein; Leslie T Cooper; Emer Joyce; Farooq H Sheikh
Journal:  J Card Fail       Date:  2021-07-11       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.